These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 29505101)
1. Evaluating Potential QT Effects of JNJ-54861911, a BACE Inhibitor in Single- and Multiple-Ascending Dose Studies, and a Thorough QT Trial With Additional Retrospective Confirmation, Using Concentration-QTc Analysis. Timmers M; Sinha V; Darpo B; Smith B; Brown R; Xue H; Ferber G; Streffer J; Russu A; Tritsmans L; Solanki B; Bogert J; Van Nueten L; Salvadore G; Nandy P J Clin Pharmacol; 2018 Jul; 58(7):952-964. PubMed ID: 29505101 [TBL] [Abstract][Full Text] [Related]
2. Concentration-QTcF Modeling of Icenticaftor from a Randomized, Placebo- and Positive-Controlled Thorough QT Study in Healthy Participants. Iyer GR; Darpo B; Xue H; Lecot J; Zack J; Bebrevska L; Weis W; Jones I; Drollmann A Clin Pharmacol Drug Dev; 2024 May; 13(5):572-584. PubMed ID: 38284433 [TBL] [Abstract][Full Text] [Related]
3. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials. Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895 [TBL] [Abstract][Full Text] [Related]
4. Assessing QT/QTc interval prolongation with concentration-QT modeling for Phase I studies: impact of computational platforms, model structures and confidence interval calculation methods. Lu J; Li J; Helmlinger G; Al-Huniti N J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):469-482. PubMed ID: 29556866 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects. Zhou D; So K; Dymond AW; Vik T; Al-Huniti N; Mariani G; Zorenyi G; Huang Y; Holmes V; Severin P; Rasmussen S; Martin P Clin Ther; 2016 Dec; 38(12):2555-2566. PubMed ID: 27837934 [TBL] [Abstract][Full Text] [Related]
6. Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects. Shakeri-Nejad K; Aslanis V; Veldandi UK; Mooney L; Pezous N; Brendani B; Juan A; Allison M; Perry R; Legangneux E Clin Ther; 2015 Nov; 37(11):2489-2505.e2. PubMed ID: 26519230 [TBL] [Abstract][Full Text] [Related]
7. Intravenous Dosing as an Alternate Approach to Safely Achieve Supratherapeutic Exposure for Assessments of Cardiac Repolarization: A Randomized Clinical Trial with Mavoglurant (AFQ056). Ufer M; Sagkriotis A; Salunke A; Ganesan S; Tisserant A; Dodman A; Voltz E; Woessner R; Jordaan P; Legangneux E Clin Ther; 2016 Dec; 38(12):2589-2597. PubMed ID: 27823869 [TBL] [Abstract][Full Text] [Related]
8. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study. Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636 [TBL] [Abstract][Full Text] [Related]
9. Can an early phase clinical pharmacology study replace a thorough QT study? Experience with a novel H3-receptor antagonist/inverse agonist. Shah RR; Maison-Blanche P; Robert P; Denis E; Duvauchelle T Eur J Clin Pharmacol; 2016 May; 72(5):533-43. PubMed ID: 26879827 [TBL] [Abstract][Full Text] [Related]
10. Effect of Retosiban on Cardiac Repolarization in a Randomized, Placebo- and Positive-controlled, Crossover Thorough QT/QTc Study in Healthy Men and Women. Stier B; Fossler M; Liu F; Caltabiano S Clin Ther; 2015 Jul; 37(7):1541-54. PubMed ID: 26138866 [TBL] [Abstract][Full Text] [Related]
11. No effect on QT intervals of mipomersen, a 2'-O-methoxyethyl modified antisense oligonucleotide targeting ApoB-100 mRNA, in a phase I dose escalation placebo-controlled study, and confirmed by a thorough QT (tQT) study, in healthy subjects. Yu RZ; Gunawan R; Li Z; Mittleman RS; Mahmood A; Grundy JS; Singleton W; Geary R; Wang Y Eur J Clin Pharmacol; 2016 Mar; 72(3):267-75. PubMed ID: 26645588 [TBL] [Abstract][Full Text] [Related]
12. A Thorough QT Study of the Combination Glecaprevir + Pibrentasvir on Cardiac Repolarization in Healthy Subjects. Oberoi RK; Zhao W; Rosebraugh M; Mensa F; Wang H; Liu W Clin Ther; 2020 Jul; 42(7):1317-1329. PubMed ID: 32622784 [TBL] [Abstract][Full Text] [Related]
13. Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects. Davis JD; Hackman F; Layton G; Higgins T; Sudworth D; Weissgerber G Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):68-75. PubMed ID: 18333868 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers. Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315 [TBL] [Abstract][Full Text] [Related]
15. Establishing assay sensitivity in QT studies: experience with the use of moxifloxacin in an early phase clinical pharmacology study and comparison with its effect in a thorough QT study. Shah RR; Maison-Blanche P; Duvauchelle T; Robert P; Denis E Eur J Clin Pharmacol; 2015 Dec; 71(12):1451-9. PubMed ID: 26423621 [TBL] [Abstract][Full Text] [Related]
16. No QTc Prolongation With Zanubrutinib: Results of Concentration-QTc Analysis From a Thorough QT Study in Healthy Subjects. Mu S; Darpo B; Tang Z; Novotny W; Tawashi M; Xue H; Willett M; Lin L; Sahasranaman S; Ou YC Clin Transl Sci; 2020 Sep; 13(5):923-931. PubMed ID: 32144955 [TBL] [Abstract][Full Text] [Related]
17. A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, Four-Period Crossover Study To Evaluate the Effect of Gepotidacin on Cardiac Conduction as Assessed by 12-Lead Electrocardiogram in Healthy Volunteers. Hossain M; Zhou M; Tiffany C; Dumont E; Darpo B Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223381 [TBL] [Abstract][Full Text] [Related]
18. Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects. Anderson K; Xin Y; Zheng H; Yun C; Kwan E; Qin A; Namour F; Kearney BP; Mathias A Clin Pharmacol Drug Dev; 2020 Jan; 9(1):32-40. PubMed ID: 31797578 [TBL] [Abstract][Full Text] [Related]
19. Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Patients With Cushing Syndrome, Does Not Cause Prolongation of the Cardiac QT Interval. Donegan DM; Pivonello R; Stigliano A; Lardo P; Kearney T; Mezősi E; Ghigo E; Giordano R; Mariash CN; Feelders RA; Donaldson K; Darpo B; Xue H; Custodio JM; Hand AL; Moraitis AG Endocr Pract; 2024 Jan; 30(1):11-18. PubMed ID: 37805100 [TBL] [Abstract][Full Text] [Related]
20. A Thorough QT Study to Evaluate the Effects of a Supratherapeutic Dose of Sertraline on Cardiac Repolarization in Healthy Subjects. Abbas R; Riley S; LaBadie RR; Bachinsky M; Chappell PB; Crownover PH; Damle B Clin Pharmacol Drug Dev; 2020 Apr; 9(3):307-320. PubMed ID: 31777203 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]